Search clinical trials for: MK0431, sitagliptin phosphate / Duration of Treatment: 21 Weeks

Total 148 results

Merck Sharp & Dohme LLC

Completed

A Study of MK0431 in Patients With Type 2 Diabetes (0431-010)

Diabetes Mellitus, Type II
Merck Sharp & Dohme LLC

Completed

MK-0431 Early Phase II Double-blind Study - Type 2 Diabetes Mellitus (0431-043)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study on the Effect of Kidney Disease on a Diabetes Medication (0431-008)

Renal Insufficiency | Hemodialysis
Merck Sharp & Dohme LLC

Completed

MK0431 (Sitagliptin) Pioglitazone Add-on Study for Patients With Type 2 Diabetes Mellitus (0431-055)(COMPLETED)

Type 2 Diabetes Mellitus
Organon and Co

Completed

A Study Comparing Ezetimibe Plus Simvastatin Versus Simvastatin Alone in Patients at Risk for Heart Disease (0653-023)(COMPLETED)

Coronary Disease
Merck Sharp & Dohme LLC

Completed

Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)

Diabetes Mellitus, Type II
Merck Sharp & Dohme LLC

Completed

An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (0431-024)

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC

Completed

A Method to Evaluate Glucose-Dependent Insulin Secretion in Healthy Males (MK-0431-179)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Clinical Study on Sitagliptin for Assessment of Glucose-lowering Effects (0431-045)

Diabetes Mellitus, Non-Insulin-Dependent
Merck Sharp & Dohme LLC

Completed

Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-021)

Diabetes Mellitus, Type 2
H. Lundbeck A/S

Terminated

Adult Polysomnography Primary Insomnia Cross Over Study (0928-049)(TERMINATED)

Primary Insomnia
Merck Sharp & Dohme LLC

Completed

Study to Assess the Efficacy and Safety of Sitagliptin in Recently Diagnosed, Naive Type 2 Diabetics With Inadequate Glycemic Control on Diet and Exercise (0431-158)

Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study of MK0431 in Patients WIth Hepatic Insufficiency (0431-017)(COMPLETED)

Liver Insufficiency
Merck Sharp & Dohme LLC

Completed

Study of Sitagliptin in Older Type 2 Diabetics (0431-047)(COMPLETED)

Type 2 Diabetes
Merck Sharp & Dohme LLC

Completed

An Open-Label, Single- & Multiple-Dose Study to Investigate the Pharmacokinetics of Sitagliptin 100 mg in Healthy Chinese Adult Subjects (0431-108)(COMPLETED)

Diabetes Mellitus Non-insulin-dependent
Merck Sharp & Dohme LLC

Completed

Sitagliptin Dose Comparison Study in Patients With Type 2 Diabetes (MK-0431-077)(COMPLETED)

Type 2 Diabetes
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety and Effectiveness of Ertapenem Versus Ceftriaxone/Metronidazole in the Treatment of Intra-abdominal Infections in Adults (0826-802)

Intra-abdominal Infection
Merck Sharp & Dohme LLC

Completed

A Study of an Investigational Drug Sitagliptin for Type 2 Diabetes Mellitus (0431-044)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Sitagliptin Comparative Study in Patients With Type 2 Diabetes (0431-049)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study of Indinavir Plus Ritonavir Plus Two NRTIs vs. Nelfinavir Plus Two NRTIs in HIV Positive Patients (0639-112)(COMPLETED)

HIV Infections
Merck Sharp & Dohme LLC

Completed

Sitagliptin Added-on to Insulin Study (0431-051)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Terminated

The Effect of Sitagliptin in Type 2 Diabetes Mellitus With Inadequate Glycemic Control (MK0431-118)

Diabetes Mellitus Non-insulin-dependent
Merck Sharp & Dohme LLC

Completed

An Investigational Drug in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (0431-028)(COMPLETED)

Diabetes Mellitus, Type 2 | Chronic Renal Insufficiency
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED)

Type 2 Diabetes Mellitus
Organon and Co

Completed

A Study to Assess the Effect of Montelukast Sodium With Concomitant Administration of Inhaled Budesonide in Asthmatic Patients (0476-075)

Asthma
Merck Sharp & Dohme LLC

Completed

MK0524A Clinical Efficacy Study (0524A-026)(COMPLETED)

Hypercholesterolemia
Merck Sharp & Dohme LLC

Completed

MK0431A Comparative Study in Patients With Type 2 Diabetes (0431A-079)(COMPLETED)

Type 2 Diabetes Mellitus
Organon and Co

Completed

Study of an Approved Drug in Patients With Asthma (0476-289)(COMPLETED)

Asthma
Organon and Co

Completed

MK0476 Study in Adult Patients With Allergic Rhinitis (0476-378)

Rhinitis Allergic
Organon and Co

Completed

A Crossover Study to Evaluate the Efficacy of Simvastatin in Elevating HDL-C Levels in Patients With Type 2 Diabetes (0733-216)(COMPLETED)

HDL Cholesterol
Organon and Co

Completed

To Evaluate the Lipid-Lowering Efficacy and Safety of Simvastatin 40 Mg Tablet In Patients With Hypercholesterolemia (0733-264)

Hypercholesterolemia

Taiwan
Merck Sharp & Dohme LLC

Completed

MK0524A Phase IIb Study (0524A-011)(COMPLETED)

Flushing
University of Colorado, Denver

Recruiting

Should Graf IIc Hips be Treated for 12 Weeks

Developmental Dysplasia of Hip

United States
Merck Sharp & Dohme LLC

Completed

MK0431 (Sitagliptin) and Metformin Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-036)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study to Test the Effectiveness and Safety of MK0893 in Combination With Other Drugs Used to Treat Type 2 Diabetes (0893-015)

Diabetes Mellitus, Type 2
Organon and Co

Completed

Linear Growth Study (0476-097)(COMPLETED)

Asthma
Organon and Co

Completed

Comparing an Investigational Medication Versus an Approved Medication in Reducing Cholesterol Levels (0653-025)

Hypercholesterolemia
Merck Sharp & Dohme LLC

Completed

Ertapenem Sodium vs. Piperacillin/Tazobactam in the Treatment of Complicated Intra-Abdominal Infections (0826-037)

Complicated Intra-Abdominal Infections
Organon and Co

Completed

A Study to Evaluate Ezetimibe in Korean Patients With Primary Hypercholesterolemia (0653-042)

Hypercholerolemia
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Pharmacokinetics, Safety and Tolerability of Sitagliptin in Adolescents (0431-081)

Type 2 Diabetes
Merck Sharp & Dohme LLC

Completed

Dose Response Finding Study of MK-0431/ONO-5435 in Japanese Subjects With Impaired Glucose Tolerance (MK-0431-105)

Glucose Intolerance
Merck Sharp & Dohme LLC

Completed

Effect of MK0524A on Flushing Caused by Niacin (0524A-056)

Flushing
Organon and Co

Completed

A Study of an Investigational Study Drug for Benign Prostatic Hyperplasia (0906-140)

Benign Prostatic Hyperplasia
Merck Sharp & Dohme LLC

Completed

Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262)

Type 2 Diabetes Mellitus
Novo Nordisk A/S

Completed

Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus. (PIONEER 7)

Diabetes Mellitus, Type 2 | Diabetes

United States, Austria, Belgium, Norway, Turkey, Switzerland, Argentina, Korea, Republic of, Brazil, Egypt
Merck Sharp & Dohme LLC

Completed

MK0431/ONO-5435 Phase III Clinical Trial -Add-on to Voglibose Study for Patients With Type 2 Diabetes Mellitus (MK0431-104)

Diabetes Mellitus, Non-Insulin-Dependent
Merck Sharp & Dohme LLC

Completed

A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy (0431-054)(COMPLETED)

Diabetes Mellitus, Non-Insulin-Dependent
H. Lundbeck A/S

Completed

MK0928 Study in Adult Patients With Primary Insomnia (0928-040)(COMPLETED)

Primary Insomnia
H. Lundbeck A/S

Terminated

Elderly Primary Insomnia Polysomnographic Study (0928-002)(TERMINATED)

Primary Insomnia
Merck Sharp & Dohme LLC

Completed

A Local Experiential Study With Sitagliptin (an Antihyperglycemic Drug) in 30 Patients With Type 2 Diabetes Mellitus (0431-178)

Type 2 Diabetes

3

Subscribe